Nicholas A.J. Botwood net worth and biography

Nicholas Botwood Biography and Net Worth

Head of Research & Development and Chief Medical Officer of Syndax Pharmaceuticals

Nicholas (Nick) Botwood, M.B.B.S., has served as our Head of Research & Development and Chief Medical Officer since May 2025.

Prior to joining Syndax, Nick held various senior leadership roles at the Bristol-Myers Squibb Company d/b/a Bristol Myers Squibb (BMS), most recently serving as the Head of Worldwide Medical Oncology, where he oversaw all medical activities in its oncology portfolio, including new asset launches, data generation, medical education and commercial strategy. From 2020 through 2022, as Senior Vice President, Head U.S. Medical, Nick was accountable for all medical planning in the United States across commercial and development, including hematology and oncology. From 2015 to 2020, he held senior clinical development roles across BMS’ oncology portfolio. Before BMS, Nick spent nearly 15 years at AstraZeneca plc, where he ultimately served as Vice President, Head of Oncology Clinical and Head of Global Clinical Operations and had direct clinical accountability for a number of established oncology brands.

Nick holds a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) from Imperial College London and a Bachelor of Science (B.S.c.) from University College London. He is a member of the Faculty of Pharmaceutical Medicine and an elected Fellow of the Royal College of Physicians UK.

How do I contact Nicholas A.J. Botwood?: The corporate mailing address for Dr. Botwood and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Nicholas A.J. Botwood's contact information.
Has Nicholas A.J. Botwood been buying or selling shares of Syndax Pharmaceuticals?: Nicholas A.J. Botwood has not been actively trading shares of Syndax Pharmaceuticals in the last ninety days. Learn More on Nicholas A.J. Botwood's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Nicholas Botwood (Head of Research & Development and Chief Medical Officer), Fabrice Egros (Director), Neil Gallagher (President, Head of Research and Development), Keith Goldan (Chief Financial Officer), Pierre Legault (Director), Michael Metzger (COO), William Meury (Director), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, insiders at the sold shares 13 times. They sold a total of 308,139 shares worth more than $5,230,285.58. The most recent insider tranaction occured on June, 12th when CMO Nicholas A.J. Botwood sold 31,235 shares worth more than $566,602.90. Insiders at Syndax Pharmaceuticals own 4.8% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 6/12/2026.

Nicholas A.J. Botwood Insider Trading History at Syndax Pharmaceuticals

Nicholas A.J. Botwood Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $18.48

$18.01

$18.55

50 Day Range

MA: $20.92

$16.96

$25.15

2 Week Range

Now: $18.48

$8.59

$25.59

Volume

1,952,514 shs

Average Volume

1,592,395 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield